An Immunohistochemical Assessment of Ki-67 and P53 Over-expression in Helicobacter pylori-positive Gastritis


  • Karam Turath Tawfeeq Department of Pathology, College of Medicine, University of Mosul, Mosul, Iraq
  • Elaf Abdulwahhab Hamdi Department of Pathology
  • Nadwa Subhi Al-Azzo Department of Pathology, College of Medicine, University of Mosul, Mosul, Iraq



Gastritis, Helicobacter pylori, Ki-67, P53


AIM: Helicobacter pylori infection of the stomach is a common disease and the resulting changes from it are many and deserve to be in the focus of researchers’ attention, to assess the expression of mutant P53 protein and Ki-67 markers in patients with gastritis secondary to H. pylori.

METHODS: Thirty samples with positive H. pylori gastritis were included in a retrospective study in Mosul/Iraq. The histological parameters were assessed using the Sydney system, then, the expression of Ki-67 and P53 expression was studied by immunohistochemical methods. The significance level was appointed at (0.05).

RESULTS: Ki-67 and P53 expression were found in 83.3% of the total cases. The study results show that 92% of positive Ki-67 and P53 cases had chronic inflammatory cell infiltration, polymorph nuclear cells infiltration, and atrophy. Whereas 96% of positive Ki-67 cases had no metaplasia, 92% of the positive P53 cases had no metaplasia. The results also showed that only 16% of the positive Ki-67 cases had dysplastic changes, and 24% of the positive cases of P53 cases were showed dysplasia. whenever P53 was negative; there is neither metaplasia nor dysplasia in the tissue, this does not apply to Ki-67 negative cases.

CONCLUSIONS: Ki-67 and P53 expressions increase with chronicity of Helicobacter pylori-positive gastritis. P53 expression is amplified when atrophy is present in these samples.


Download data is not yet available.


Metrics Loading ...

Plum Analytics Artifact Widget Block


Fischbach W, Malfertheiner P, Lynen Jansen P, Bolten W, Bornschein J, Buderus S, et al. S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease. Z Gastroenterol. 2016;54(4):327-63. PMid:27919112 DOI:

Sipponen P, Maaroos HI. Chronic gastritis. Scand J Gastroenterol. 2015;50(6):657-67. PMid:25901896 DOI:

Kim KM, Oh YL, Ko JS, Choe YH, Seo JK. Histopathology and expression of Ki-67 and cyclooxygenase-2 in childhood Helicobacter pylori gastritis. J Gastroenterol. 2004;39(3):231-7. PMid:15064999 DOI:

Kamimura K, Kobayashi M, Sato Y, Aoyagi Y, Terai S. Collagenous gastritis: Review. World J Gastrointest Endosc. 2015;7(3):265-73. PMid:25789098 DOI:

Kulnigg-Dabsch S. Autoimmune gastritis. Wien Med Wochensch (1946). 2016;166(13-14):424-30. PMid:27671008 DOI:

Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67. PMid:26187502 DOI:

Watari J, Chen N, Amenta PS, Fukui H, Oshima T, Tomita T, et al. Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. World J Gastroenterol. 2014;20(18):5461-73. PMid:24833876 DOI:

Nayak VH, Engin NY, Burns JJ, Ameta P. Hypereosinophilic syndrome with eosinophilic gastritis. Global Pediatr Health. 2017;4:2333794X17705239. PMid:28491930 DOI:

Rodriguez-Castro KI, Franceschi M, Miraglia C, Russo M, Nouvenne A, Leandro G, et al. Autoimmune diseases in autoimmune atrophic gastritis. Acta Biomed. 2018;89(8-S):100-3. PMid:30561426

Wei J, Nagy TA, Vilgelm A, Zaika E, Ogden SR, Romero-Gallo J, et al. Regulation of p53 tumor suppressor by Helicobacter pylori in gastric epithelial cells. Gastroenterology. 2010;139(4):1333-43. PMid:20547161 DOI:

Mbulaiteye SM, Hisada M, El-Omar EM. Helicobacter pylori associated global gastric cancer burden. Front Biosci (Landmark edition). 2009;14:1490-504. PMid:19273142 DOI:

Al-Hassany HA, Albu-Rghaif AH, Naji MA. Tumor diagnosis by genetic markers protein P-53, p16, C-MYC, N-MYC, protein K-Ras, and gene her-2 Neu is this possible? Tumor diagnosis by genetic markers C-MYC, N-MYC, protein P-53, p16. Pak J Med Health Sci 2021;15(8):2350-4. DOI:

Tawfeeq KT, SHSA-T. P53 over-expression in urothelial carcinoma of the bladder: An immunohistochemical study. Med J Tikrit Univ 2012;18(182):189-211.

Salih BA, Gucin Z, Bayyurt N. A study on the effect of Helicobacter pylori infection on p53 expression in gastric cancer and gastritis tissues. J Infect Dev Ctries. 2013;7(9):651-7. PMid:24042100 DOI:

Shadifar M, Ataee R, Ataie A, Heydari Gorgi AM, Nasri Nasrabadi N, Nouri S. Genetic and molecular aspects of Helicobacter pylori in gastritis, pre- cancerous conditions and gastric adenocrcinoma. Gastroenterol Hepatol Bed Bench. 2015;8(Suppl 1):S15-22. PMid:26171133

Sun X, Kaufman PD. Ki-67: More than a proliferation marker. Chromosoma. 2018;127(2):175-86. PMid:29322240 DOI:

Cabral MM, Oliveira CA, Mendes CM, Guerra J, Queiroz DM, Rocha GA, et al. Gastric epithelial cell proliferation and cagA status in Helicobacter pylori gastritis at different gastric sites. Scand J Gastroenterol. 2007;42(5):545-54. PMid:17454874 DOI:

Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: Results of the PALMS study. J Natl Cancer Inst. 2013;105(20):1550-7. PMid:24096620 DOI:

Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke- Lüthge A, Bergeron C, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol. 2011;121(3):505-9. PMid:21420158 DOI:

Wentzensen N, Schwartz L, Zuna RE, Smith K, Mathews C, Gold MA, et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res. 2012;18(15):4154-62. PMid:22675168 DOI:

Ahadi M, Moradi A, Musavinejad L, Movafagh A, Moradi A. The expression of p53, CD44, Ki-67, and HER-2/ neu markers in gastric cancer and its association with histopathological indicators: A retrospective study. Asian Pac J Cancer Prev. 2020;21(6):1607-14. PMid:32592354 DOI:

Li N, Xie C, Lu NH. p53, a potential predictor of Helicobacter pylori infection-associated gastric carcinogenesis? Oncotarget. 2016;7(40):66276-86. DOI:

Mahmoudzadeh Sagheb H, Heidari Z, Jahantigh M, Narouei M. Immunohistochemical expression of p53 and Ki-67 genes in gastric cancer and precancerous lesions in the patients with Helicobacter pylori infection. Gene Cell Tissue. 2016;3(4):e41341. DOI:

Tiwari E, Pallipady A, Misra R, Mishra S. P53 and ki67 immunostaining in gastric biopsies: A histopathological study. Int J Sci Study 2015;2(11):96-101.

Azza Hegazi EH, El-Atrebi KA, El-Bassyouni HT. “P53 protein and Ki-67 expression in chronic gastritis patients with positive Helicobacter pylori infection”. J Gen Eng Biotechnol 2011;9(1): 73-76. DOI:

Gobbo César AC, de Freitas Calmon M, Cury PM, Caetano A, Borim AA, Silva AE. Genetic alterations in benign lesions: Chronic gastritis and gastric ulcer. World J Gastroenterol. 2006;12(4):625-9. PMid:16489680 DOI:

Elnashar AT, Ahmed AR, Mohammed MH, Kamal GM. Immunohistochemical detection of P53 in Helicobacter pylori gastritis. Cancer Biol 2016;6(2):30-7.

Morales-Fuentes GA, Zarate-Osorno A, Quiñónez-Urrego EE, Antonio-Manrique M, Martínez-García CL, Figueroa-Barojas P, et al. p53 expression in the gastric mucosa of patients infected with Helicobacter pylori. Rev Gastroenterol Mexico. 2013;78(1):12-20. PMid:23374541 DOI:

Aziz ZW, Saleem SH, Al-Nuaimy HA. Helicobacter pylori in gastric biopsy: A histochemical and immunohistochemical assessment. Ann Coll Med Mosul. 2020;41(2):139-47. DOI:

Forones NM, Carvalho AP, Giannotti-Filho O, Lourenço LG, Oshima CT. Cell proliferation and apoptosis in gastric cancer and intestinal metaplasia. Arq Gastroenterologia. 2005;42(1):30-4. PMid:15976908 DOI:




How to Cite

Tawfeeq KT, Hamdi EA, Al-Azzo NS. An Immunohistochemical Assessment of Ki-67 and P53 Over-expression in Helicobacter pylori-positive Gastritis. Open Access Maced J Med Sci [Internet]. 2022 Mar. 10 [cited 2024 Apr. 18];10(A):535-9. Available from: